Research Management Committee

INDEPENDENT. INTERNATIONAL. LEADERS.

 

The Research Management Committee (RMC) is made up of independent members whose primary role is to evaluate research proposals and actively help BioCanRx monitor the progress of its projects. The RMC will build and maintain a robust, competitive research portfolio founded on scientific excellence and network goals. All RMC funding and budget recommendations go to the Board of Directors for approval.

 

In order to avoid potential conflicts of interest, the voting RMC is composed of independent and primarily international experts in biotherapeutics.

 

Membership

 

jhoch
smandrekar
Dr. Dmitriy Zamarin
Medical Oncologist, Section Head, Gynecologic Medical Oncology at Icahn School of Medicine at Mount Sinai
Dr. Awen Gallimore
Professor, Immunology, Infection and Immunity, Cardiff University
Dr. Jeffrey Hoch
Professor, Department of Public Health Sciences, UC Davis
Dr. Sumithra Mandrekar
Professor of Biostatistics and Oncology at the Mayo Clinic (USA)
alanmelcher-1
clionarooney-1
Michael Mee
Principal, Amplitude Ventures
Dr. Alan Melcher
Professor of Translational Immunotherapy, The Institute of Cancer Research, Chester Beatty Laboratories, London (UK)
Dr. Isabelle Rivière
Vice President, Head of Oncology Cell Therapy Technologies and Product Engine, Takeda
Dr. Cliona Rooney
Professor, Baylor College of Medicine (USA)
len-seymour
Dr. Bruce Seet
Head of Medical Affairs (Canada) at Novavax
Dr. Len Seymour
Professor of Gene Therapy, University of Oxford

 

EX-OFFICIO MEMBERS (NON-VOTING)

 

Dr. John Bell
BioCanRx Scientific Director
Senior Scientist, the Ottawa Hospital Research Institute
Professor, uOttawa

 

Dr. Kelvin Chan
Associate Scientist, Sunnybrook Health Sciences Centre (Canada)

 

Dr. Douglas Mahoney
Associate Professor of Microbiology, Immunology, and Infectious Disease
Associate Director, Basic and Translational Research, Charbonneau Cancer Institute
Scientific Director, Alberta Cell Therapy and Immune Oncology (ACTION) Initiative
Director, Riddell Centre for Cancer Immunotherapy

 

Dr. Brad Nelson
BioCanRx Theme Leader
Director and Distinguished Scientist, Deeley Research Centre, BCCA
Professor, Biochemistry and Microbiology, University of Victoria

 

Dr. Claude Perreault
Principal Investigator, IRIC
Professor, Faulty of Medicine, Université de Montréal
Hematologist, Maisonneuve-Rosemont Hospital

 

 

OBSERVERS

 

Dr. Stéphanie Michaud
President and CEO, BioCanRx

 

Megan Mahoney, PhD
Director, Scientific Affairs and Training Programs

 

Julie Jonkhans, PhD
Training and Research Manager